Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Administración de suplementos de ácidos grasos poliinsaturados a los lactantes para la prevención de la alergia

Información

DOI:
https://doi.org/10.1002/14651858.CD010112.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 28 octubre 2016see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Neonatología

Copyright:
  1. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Tim Schindler

    Correspondencia a: Department of Newborn Care, Royal Hospital for Women, Randwick, Australia

    [email protected]

  • John KH Sinn

    Department of Neonatology, Royal North Shore Hospital, The University of Sydney, Sydney, Australia

  • David A Osborn

    Central Clinical School, Discipline of Obstetrics, Gynaecology and Neonatology, University of Sydney, Sydney, Australia

Contributions of authors

TS, DAO and JKS contributed to the protocol.
TS and DAO performed the literature search, independently assessed studies for eligibility, performed critical appraisal of eligible studies and data extraction, and formed a consensus on the conclusions.
TS wrote the review with DAO.

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • Australian Satellite of the Cochrane Neonatal Review Group, Australia.

    NH&MRC grant RIMS project ID: 2013‐01632

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, USA.

    Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C

Declarations of interest

None known.

Acknowledgements

We would like to thank external referee Janet Berrington.

Version history

Published

Title

Stage

Authors

Version

2016 Oct 28

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy

Review

Tim Schindler, John KH Sinn, David A Osborn

https://doi.org/10.1002/14651858.CD010112.pub2

2012 Sep 12

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy and food hypersensitivity

Protocol

Tim Schindler, Lauren Gladman, John KH Sinn, David A Osborn

https://doi.org/10.1002/14651858.CD010112

Differences between protocol and review

The protocol listed food hypersensitivity as a secondary outcome. We have omitted this as the review is focused on clinical allergic outcomes. The term 'hypersensitivity' includes clinical reactions that are not related to allergy.

In the review, we excluded studies that included eligible participants and compared eligible interventions but did not prespecify or report allergy. Although it was intended to include these to facilitate the assessment of publication bias, this would have resulted in an excessively cumbersome review. The potential for publication bias has still been addressed.

Risk differences are reported for all outcomes despite not being prespecified in the protocol.

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Child; Child, Preschool; Humans; Infant;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 1

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Higher versus lower PUFA intake, Outcome 1 All allergic disease.
Figuras y tablas -
Analysis 1.1

Comparison 1 Higher versus lower PUFA intake, Outcome 1 All allergic disease.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Higher versus lower PUFA intake, Outcome 2 Asthma.
Figuras y tablas -
Analysis 1.2

Comparison 1 Higher versus lower PUFA intake, Outcome 2 Asthma.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Higher versus lower PUFA intake, Outcome 3 Dermatitis/eczema.
Figuras y tablas -
Analysis 1.3

Comparison 1 Higher versus lower PUFA intake, Outcome 3 Dermatitis/eczema.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Higher versus lower PUFA intake, Outcome 4 Allergic rhinitis.
Figuras y tablas -
Analysis 1.4

Comparison 1 Higher versus lower PUFA intake, Outcome 4 Allergic rhinitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Higher versus lower PUFA intake, Outcome 5 Food allergy.
Figuras y tablas -
Analysis 1.5

Comparison 1 Higher versus lower PUFA intake, Outcome 5 Food allergy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 1 All allergic disease ‐ infant incidence.
Figuras y tablas -
Analysis 2.1

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 1 All allergic disease ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 2 All allergic disease ‐ childhood incidence.
Figuras y tablas -
Analysis 2.2

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 2 All allergic disease ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 3 All allergic disease ‐ childhood prevalence.
Figuras y tablas -
Analysis 2.3

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 3 All allergic disease ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 4 Asthma ‐ infant incidence.
Figuras y tablas -
Analysis 2.4

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 4 Asthma ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 5 Asthma ‐ childhood incidence.
Figuras y tablas -
Analysis 2.5

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 5 Asthma ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 6 Asthma ‐ childhood prevalence.
Figuras y tablas -
Analysis 2.6

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 6 Asthma ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 7 Dermatitis/eczema ‐ infant incidence.
Figuras y tablas -
Analysis 2.7

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 7 Dermatitis/eczema ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 8 Dermatitis/eczema ‐ childhood incidence.
Figuras y tablas -
Analysis 2.8

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 8 Dermatitis/eczema ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.
Figuras y tablas -
Analysis 2.9

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 10 Allergic rhinitis ‐ infant incidence.
Figuras y tablas -
Analysis 2.10

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 10 Allergic rhinitis ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 11 Allergic rhinitis ‐ childhood prevalence.
Figuras y tablas -
Analysis 2.11

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 11 Allergic rhinitis ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 12 Food allergy ‐ infant incidence.
Figuras y tablas -
Analysis 2.12

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 12 Food allergy ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 13 Food allergy ‐ childhood incidence.
Figuras y tablas -
Analysis 2.13

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 13 Food allergy ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 14 Food allergy ‐ childhood prevalence.
Figuras y tablas -
Analysis 2.14

Comparison 2 Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother, Outcome 14 Food allergy ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 1 All allergic disease ‐ infant incidence.
Figuras y tablas -
Analysis 3.1

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 1 All allergic disease ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 2 All allergic disease ‐ childhood incidence.
Figuras y tablas -
Analysis 3.2

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 2 All allergic disease ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 3 All allergic disease ‐ childhood prevalence.
Figuras y tablas -
Analysis 3.3

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 3 All allergic disease ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 4 Asthma ‐ infant incidence.
Figuras y tablas -
Analysis 3.4

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 4 Asthma ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 5 Asthma ‐ childhood incidence.
Figuras y tablas -
Analysis 3.5

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 5 Asthma ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 6 Asthma ‐ childhood prevalence.
Figuras y tablas -
Analysis 3.6

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 6 Asthma ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 7 Dermatitis/eczema ‐ infant incidence.
Figuras y tablas -
Analysis 3.7

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 7 Dermatitis/eczema ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 8 Dermatitis/eczema ‐ childhood incidence.
Figuras y tablas -
Analysis 3.8

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 8 Dermatitis/eczema ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.
Figuras y tablas -
Analysis 3.9

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 10 Allergic rhinitis ‐ infant incidence.
Figuras y tablas -
Analysis 3.10

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 10 Allergic rhinitis ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 11 Allergic rhinitis ‐ childhood prevalence.
Figuras y tablas -
Analysis 3.11

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 11 Allergic rhinitis ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 12 Food allergy ‐ infant incidence.
Figuras y tablas -
Analysis 3.12

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 12 Food allergy ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 13 Food allergy ‐ childhood incidence.
Figuras y tablas -
Analysis 3.13

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 13 Food allergy ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 14 Food allergy ‐ childhood prevalence.
Figuras y tablas -
Analysis 3.14

Comparison 3 Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation, Outcome 14 Food allergy ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 1 All allergic disease ‐ infant incidence.
Figuras y tablas -
Analysis 4.1

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 1 All allergic disease ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 2 All allergic disease ‐ childhood incidence.
Figuras y tablas -
Analysis 4.2

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 2 All allergic disease ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 3 All allergic disease ‐ childhood prevalence.
Figuras y tablas -
Analysis 4.3

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 3 All allergic disease ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 4 Asthma ‐ infant incidence.
Figuras y tablas -
Analysis 4.4

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 4 Asthma ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 5 Asthma ‐ childhood incidence.
Figuras y tablas -
Analysis 4.5

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 5 Asthma ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 6 Asthma ‐ childhood prevalence.
Figuras y tablas -
Analysis 4.6

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 6 Asthma ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 7 Dermatitis/eczema ‐ infant incidence.
Figuras y tablas -
Analysis 4.7

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 7 Dermatitis/eczema ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 8 Dermatitis/eczema ‐ childhood incidence.
Figuras y tablas -
Analysis 4.8

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 8 Dermatitis/eczema ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.
Figuras y tablas -
Analysis 4.9

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 10 Allergic rhinitis ‐ infant incidence.
Figuras y tablas -
Analysis 4.10

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 10 Allergic rhinitis ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 11 Allergic rhinitis ‐ childhood prevalence.
Figuras y tablas -
Analysis 4.11

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 11 Allergic rhinitis ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 12 Food allergy ‐ infant incidence.
Figuras y tablas -
Analysis 4.12

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 12 Food allergy ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 13 Food allergy ‐ childhood incidence.
Figuras y tablas -
Analysis 4.13

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 13 Food allergy ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 14 Food allergy ‐ childhood prevalence.
Figuras y tablas -
Analysis 4.14

Comparison 4 Higher versus lower PUFA intake: subgrouped by method of infant feeding, Outcome 14 Food allergy ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 1 All allergic disease ‐ infant incidence.
Figuras y tablas -
Analysis 5.1

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 1 All allergic disease ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 2 All allergic disease ‐ childhood incidence.
Figuras y tablas -
Analysis 5.2

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 2 All allergic disease ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 3 All allergic disease ‐ childhood prevalence.
Figuras y tablas -
Analysis 5.3

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 3 All allergic disease ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 4 Asthma ‐ infant incidence.
Figuras y tablas -
Analysis 5.4

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 4 Asthma ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 5 Asthma ‐ childhood incidence.
Figuras y tablas -
Analysis 5.5

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 5 Asthma ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 6 Asthma ‐ childhood prevalence.
Figuras y tablas -
Analysis 5.6

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 6 Asthma ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 7 Dermatitis/eczema ‐ infant incidence.
Figuras y tablas -
Analysis 5.7

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 7 Dermatitis/eczema ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 8 Dermatitis/eczema ‐ childhood incidence.
Figuras y tablas -
Analysis 5.8

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 8 Dermatitis/eczema ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.
Figuras y tablas -
Analysis 5.9

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 10 Allergic rhinitis ‐ infant incidence.
Figuras y tablas -
Analysis 5.10

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 10 Allergic rhinitis ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 11 Allergic rhinitis ‐ childhood prevalence.
Figuras y tablas -
Analysis 5.11

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 11 Allergic rhinitis ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 12 Food allergy ‐ infant incidence.
Figuras y tablas -
Analysis 5.12

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 12 Food allergy ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 13 Food allergy ‐ childhood incidence.
Figuras y tablas -
Analysis 5.13

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 13 Food allergy ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 14 Food allergy ‐ childhood prevalence.
Figuras y tablas -
Analysis 5.14

Comparison 5 Higher versus lower PUFA intake: subgrouped by infant heredity for allergy, Outcome 14 Food allergy ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 1 All allergic disease ‐ infant incidence.
Figuras y tablas -
Analysis 6.1

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 1 All allergic disease ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 2 All allergic disease ‐ childhood incidence.
Figuras y tablas -
Analysis 6.2

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 2 All allergic disease ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 3 All allergic disease ‐ childhood prevalence.
Figuras y tablas -
Analysis 6.3

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 3 All allergic disease ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 4 Asthma ‐ infant incidence.
Figuras y tablas -
Analysis 6.4

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 4 Asthma ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 5 Asthma ‐ childhood incidence.
Figuras y tablas -
Analysis 6.5

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 5 Asthma ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 6 Asthma ‐ childhood prevalence.
Figuras y tablas -
Analysis 6.6

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 6 Asthma ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 7 Dermatitis/eczema ‐ infant incidence.
Figuras y tablas -
Analysis 6.7

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 7 Dermatitis/eczema ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 8 Dermatitis/eczema ‐ childhood incidence.
Figuras y tablas -
Analysis 6.8

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 8 Dermatitis/eczema ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.
Figuras y tablas -
Analysis 6.9

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 9 Dermatitis/eczema ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 10 Allergic rhinitis ‐ infant incidence.
Figuras y tablas -
Analysis 6.10

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 10 Allergic rhinitis ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 11 Allergic rhinitis ‐ childhood prevalence.
Figuras y tablas -
Analysis 6.11

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 11 Allergic rhinitis ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 12 Food allergy ‐ infant incidence.
Figuras y tablas -
Analysis 6.12

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 12 Food allergy ‐ infant incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 13 Food allergy ‐ childhood incidence.
Figuras y tablas -
Analysis 6.13

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 13 Food allergy ‐ childhood incidence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 14 Food allergy ‐ childhood prevalence.
Figuras y tablas -
Analysis 6.14

Comparison 6 Higher versus lower PUFA intake: subgrouped by gestational age at birth, Outcome 14 Food allergy ‐ childhood prevalence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 1 Asthma.
Figuras y tablas -
Analysis 7.1

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 1 Asthma.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 2 Dermatitis/eczema.
Figuras y tablas -
Analysis 7.2

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 2 Dermatitis/eczema.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 3 Allergic rhinitis.
Figuras y tablas -
Analysis 7.3

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 3 Allergic rhinitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 4 Food allergy.
Figuras y tablas -
Analysis 7.4

Comparison 7 Higher versus lower PUFA intake: sensitivity analysis, Outcome 4 Food allergy.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Summary of findings for the main comparison. Higher versus lower PUFA intake for the prevention of allergy ‐ infant incidence

Higher versus lower PUFA intake for the prevention of allergy ‐ infant incidence

Patient or population: infants
Settings: hospital or community
Intervention: higher versus lower PUFA intake

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Lower PUFA intake

Higher PUFA intake

All allergic disease ‐ infant incidence
Follow‐up: 1 years

Study population

RR 0.96
(0.73 to 1.26)

323
(1 study)

⊕⊝⊝⊝
very low1,2,3

‐

395 per 1000

379 per 1000
(289 to 498)

Moderate

395 per 1000

379 per 1000
(288 to 498)

Asthma ‐ infant incidence
Follow‐up: 2 years

Study population

RR 1.04
(0.8 to 1.35)

1162
(3 studies)

⊕⊕⊝⊝
low4,5

‐

160 per 1000

167 per 1000
(128 to 217)

Moderate

124 per 1000

129 per 1000
(99 to 167)

Dermatitis/eczema ‐ infant incidence
Follow‐up: 2 years

Study population

RR 0.93
(0.82 to 1.06)

1906
(7 studies)

⊕⊝⊝⊝
very low3,4,5

‐

326 per 1000

303 per 1000
(267 to 346)

Moderate

323 per 1000

300 per 1000
(265 to 342)

Allergic rhinitis ‐ infant incidence
Follow‐up: 2 years

Study population

RR 0.47
(0.23 to 0.96)

594
(2 studies)

⊕⊝⊝⊝
very low3,4,5,6

‐

74 per 1000

35 per 1000
(17 to 71)

Moderate

58 per 1000

27 per 1000
(13 to 56)

Food allergy ‐ infant incidence
Follow‐up: 2 years

Study population

RR 0.81
(0.56 to 1.19)

915
(3 studies)

⊕⊝⊝⊝
very low3,4,5,7

‐

118 per 1000

95 per 1000
(66 to 140)

Moderate

150 per 1000

121 per 1000
(84 to 179)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; PUFA: polyunsaturated fatty acid; RR: risk ratio.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Losses to follow‐up
2 Reported by single study only.
3 Wide confidence intervals.
4 Single high quality study.
5 Reported by a minority of studies.
6 Single study reported an effect.
7 Substantial heterogeneity.

Figuras y tablas -
Summary of findings for the main comparison. Higher versus lower PUFA intake for the prevention of allergy ‐ infant incidence
Ir a la tabla de la revisión
Summary of findings 2. Higher versus lower PUFA intake for the prevention of allergy ‐ childhood incidence

Higher versus lower PUFA intake for the prevention of allergy ‐ childhood incidence

Patient or population: infants
Settings: hospital or community
Intervention: higher versus lower PUFA intake

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Lower PUFA intake

Higher PUFA intake

All allergic disease ‐ childhood incidence
Follow‐up: 3 years

Study population

RR 0.69
(0.47 to 1.02)

154
(2 studies)

⊕⊝⊝⊝
very low1,2,3,4

‐

519 per 1000

358 per 1000
(244 to 529)

Moderate

483 per 1000

333 per 1000
(227 to 493)

Asthma ‐ childhood incidence
Follow‐up: 3 years

Study population

RR 0.45
(0.2 to 1.02)

89
(1 study)

⊕⊝⊝⊝
very low1,3,5

‐

353 per 1000

159 per 1000
(71 to 360)

Moderate

353 per 1000

159 per 1000
(71 to 360)

Dermatitis/eczema ‐ childhood incidence
Follow‐up: 3 years

Study population

RR 0.65
(0.34 to 1.24)

154
(2 studies)

⊕⊝⊝⊝
very low1,3,4

‐

266 per 1000

173 per 1000
(90 to 330)

Moderate

238 per 1000

155 per 1000
(81 to 295)

Food allergy ‐ childhood incidence
Follow‐up: 3 years

Study population

RR 2.27
(0.25 to 20.68)

65
(1 study)

⊕⊝⊝⊝
very low1,3,5

‐

36 per 1000

81 per 1000
(9 to 739)

Moderate

36 per 1000

82 per 1000
(9 to 744)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; PUFA: polyunsaturated fatty acid; RR: risk ratio.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Very high losses to follow‐up.
2 Moderate heterogeneity.
3 Wide confidence intervals.
4 Minority of studies reported outcome.
5 Reported by single study.

Figuras y tablas -
Summary of findings 2. Higher versus lower PUFA intake for the prevention of allergy ‐ childhood incidence
Ir a la tabla de la revisión
Summary of findings 3. Higher versus lower PUFA intake for the prevention of allergy ‐ Childhood prevalence

Higher versus lower PUFA intake for the prevention of allergy ‐ childhood prevalence

Patient or population: infants
Settings: hospital or community
Intervention: higher versus lower PUFA intake

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Lower PUFA intake

Higher PUFA intake

All allergic disease ‐ childhood prevalence
Follow‐up: 3 years

Study population

RR 0.98
(0.81 to 1.19)

633
(2 studies)

⊕⊝⊝⊝
very low1,2,3

‐

394 per 1000

386 per 1000
(319 to 469)

Moderate

372 per 1000

365 per 1000
(301 to 443)

Asthma ‐ childhood prevalence
Follow‐up: 3 years

Study population

RR 1.12
(0.82 to 1.53)

635
(2 studies)

⊕⊝⊝⊝
very low1,3,4,5

‐

188 per 1000

210 per 1000
(154 to 287)

Moderate

164 per 1000

184 per 1000
(134 to 251)

Dermatitis/eczema ‐ childhood prevalence
Follow‐up: 3 years

Study population

RR 0.81
(0.59 to 1.09)

635
(2 studies)

⊕⊝⊝⊝
very low1,2,3

‐

229 per 1000

186 per 1000
(135 to 250)

Moderate

219 per 1000

177 per 1000
(129 to 239)

Allergic rhinitis ‐ childhood prevalence
Follow‐up: 3 years

Study population

RR 1.02
(0.83 to 1.25)

635
(2 studies)

⊕⊝⊝⊝
very low1,2,3

‐

331 per 1000

338 per 1000
(275 to 414)

Moderate

220 per 1000

224 per 1000
(183 to 275)

Food allergy ‐ childhood prevalence
Follow‐up: 3 years

Study population

RR 0.27
(0.06 to 1.19)

119
(1 study)

⊕⊝⊝⊝
very low2,4

‐

138 per 1000

37 per 1000
(8 to 165)

Moderate

139 per 1000

38 per 1000
(8 to 165)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; PUFA: polyunsaturated fatty acid; RR: risk ratio.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Losses to follow‐up > 10%.
2 Wide confidence intervals.
3 Reported by a minority of studies.
4 Reported by single study.
5 Very high losses to follow‐up.

Figuras y tablas -
Summary of findings 3. Higher versus lower PUFA intake for the prevention of allergy ‐ Childhood prevalence
Ir a la tabla de la revisión
Comparison 1. Higher versus lower PUFA intake

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Infant incidence

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

1.2 Childhood incidence

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.47, 1.02]

1.3 Childhood prevalence

2

633

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.19]

2 Asthma Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Infant incidence

3

1162

Risk Ratio (M‐H, Fixed, 95% CI)

1.04 [0.80, 1.35]

2.2 Childhood incidence

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

2.3 Childhood prevalence

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.82, 1.53]

3 Dermatitis/eczema Show forest plot

9

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Infant incidence

7

1906

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.82, 1.06]

3.2 Childhood incidence

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.34, 1.24]

3.3 Childhood prevalence

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.59, 1.09]

4 Allergic rhinitis Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Infant incidence

2

594

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.23, 0.96]

4.2 Childhood prevalence

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.83, 1.25]

5 Food allergy Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Infant incidence

3

915

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.56, 1.19]

5.2 Childhood incidence

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

5.3 Childhood prevalence

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 1. Higher versus lower PUFA intake
Ir a la tabla de la revisión
Comparison 2. Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease ‐ infant incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Infant supplementation

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

2 All allergic disease ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Infant supplementation

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.34, 0.92]

2.2 Maternal supplementation

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.51, 1.91]

3 All allergic disease ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Infant supplementation

1

516

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.83, 1.25]

3.2 Maternal supplementation

1

117

Risk Ratio (M‐H, Fixed, 95% CI)

0.78 [0.44, 1.38]

4 Asthma ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Infant supplementation

1

554

Risk Ratio (M‐H, Fixed, 95% CI)

1.19 [0.78, 1.81]

4.2 Maternal supplementation

2

608

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.69, 1.33]

5 Asthma ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Infant supplementation

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

6 Asthma ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Infant supplementation

1

516

Risk Ratio (M‐H, Fixed, 95% CI)

1.13 [0.82, 1.57]

6.2 Maternal supplementation

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

1.05 [0.41, 2.72]

7 Dermatitis/eczema ‐ infant incidence Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 Infant supplementation

5

1245

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.82, 1.11]

7.2 Maternal supplementation

3

661

Risk Ratio (M‐H, Fixed, 95% CI)

0.88 [0.68, 1.15]

8 Dermatitis/eczema ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 Infant supplementation

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.55 [0.25, 1.20]

8.2 Maternal supplementation

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.28, 3.20]

9 Dermatitis/eczema ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 Infant supplementation

1

516

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.62, 1.18]

9.2 Maternal supplementation

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.23, 1.36]

10 Allergic rhinitis ‐ infant incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 Maternal supplementation

2

594

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.23, 0.96]

11 Allergic rhinitis ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 Infant supplementation

1

516

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.83, 1.25]

11.2 Maternal supplementation

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

1.20 [0.18, 8.26]

12 Food allergy ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 Infant supplementation

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.47, 1.42]

12.2 Maternal supplementation

2

592

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.48, 1.37]

13 Food allergy ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 Maternal supplementation

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

14 Food allergy ‐ childhood prevalence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 Maternal supplementation

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 2. Higher versus lower PUFA intake: subgrouped by supplementation of infant versus supplementation of mother
Ir a la tabla de la revisión
Comparison 3. Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease ‐ infant incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 n‐3 supplementation

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

2 All allergic disease ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 n‐3 supplementation

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.47, 1.02]

3 All allergic disease ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 n‐3 supplementation

2

633

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.19]

4 Asthma ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 n‐3 supplementation

3

1162

Risk Ratio (M‐H, Fixed, 95% CI)

1.04 [0.80, 1.35]

5 Asthma ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 n‐3 supplementation

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

6 Asthma ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 n‐3 supplementation

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.82, 1.53]

7 Dermatitis/eczema ‐ infant incidence Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 n‐3 supplementation

5

1657

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.82, 1.09]

7.2 n‐6 supplementation

2

249

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.59, 1.23]

8 Dermatitis/eczema ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 n‐3 supplementation

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.34, 1.24]

9 Dermatitis/eczema ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 n‐3 supplementation

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.59, 1.09]

10 Allergic rhinitis ‐ infant incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 n‐3 supplementation

2

594

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.23, 0.96]

11 Allergic rhinitis ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 n‐3 supplementation

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.83, 1.25]

12 Food allergy ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 n‐3 supplementation

3

915

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.56, 1.19]

13 Food allergy ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 n‐3 supplementation

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

14 Food allergy ‐ childhood prevalence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 n‐3 supplementation

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 3. Higher versus lower PUFA intake: subgrouped by n‐3 versus n‐6 supplementation
Ir a la tabla de la revisión
Comparison 4. Higher versus lower PUFA intake: subgrouped by method of infant feeding

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease ‐ infant incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Human milk fed infants

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

2 All allergic disease ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Human milk fed infants

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.51, 1.91]

2.2 Formula fed infants

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.34, 0.92]

3 All allergic disease ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Human milk fed infants

2

633

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.19]

4 Asthma ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5 Asthma ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Formula fed infants

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

6 Asthma ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Human milk fed infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.82, 1.53]

7 Dermatitis/eczema ‐ infant incidence Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 Human milk fed infants

6

1715

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.82, 1.09]

7.2 Formula fed infants

2

191

Risk Ratio (M‐H, Fixed, 95% CI)

0.84 [0.57, 1.23]

8 Dermatitis/eczema ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 Human milk fed infants

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.28, 3.20]

8.2 Formula fed infants

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.55 [0.25, 1.20]

9 Dermatitis/eczema ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 Human milk fed infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.59, 1.09]

10 Allergic rhinitis ‐ infant incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 Human milk fed infants

2

594

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.23, 0.96]

11 Allergic rhinitis ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 Human milk fed infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.83, 1.25]

12 Food allergy ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 Human milk fed infants

3

915

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.56, 1.19]

13 Food allergy ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 Human milk fed infants

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

14 Food allergy ‐ childhood prevalence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 Human milk fed infants

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 4. Higher versus lower PUFA intake: subgrouped by method of infant feeding
Ir a la tabla de la revisión
Comparison 5. Higher versus lower PUFA intake: subgrouped by infant heredity for allergy

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease ‐ infant incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 High risk for allergy

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

2 All allergic disease ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Risk for allergy not selected

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.47, 1.02]

3 All allergic disease ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 High risk for allergy

2

633

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.19]

4 Asthma ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 High risk for allergy

2

673

Risk Ratio (M‐H, Fixed, 95% CI)

1.16 [0.79, 1.71]

4.2 Risk for allergy not selected

1

489

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.66, 1.34]

5 Asthma ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Risk for allergy not selected

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

6 Asthma ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 High risk for allergy

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.82, 1.53]

7 Dermatitis/eczema ‐ infant incidence Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 High risk for allergy

5

1245

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.81, 1.12]

7.2 Risk for allergy not selected

2

661

Risk Ratio (M‐H, Fixed, 95% CI)

0.89 [0.71, 1.12]

8 Dermatitis/eczema ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 Risk for allergy not selected

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.34, 1.24]

9 Dermatitis/eczema ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 High risk for allergy

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.59, 1.09]

10 Allergic rhinitis ‐ infant incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 High risk for allergy

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

1.20 [0.18, 8.26]

10.2 Risk for allergy not selected

1

475

Risk Ratio (M‐H, Fixed, 95% CI)

0.40 [0.18, 0.89]

11 Allergic rhinitis ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 High risk for allergy

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.83, 1.25]

12 Food allergy ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 High risk for allergy

2

442

Risk Ratio (M‐H, Fixed, 95% CI)

0.62 [0.38, 1.02]

12.2 Risk for allergy not selected

1

473

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.67, 2.31]

13 Food allergy ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 Risk for allergy not selected

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

14 Food allergy ‐ childhood prevalence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 High risk for allergy

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 5. Higher versus lower PUFA intake: subgrouped by infant heredity for allergy
Ir a la tabla de la revisión
Comparison 6. Higher versus lower PUFA intake: subgrouped by gestational age at birth

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 All allergic disease ‐ infant incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Term infants

1

323

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.73, 1.26]

2 All allergic disease ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Term infants

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.47, 1.02]

3 All allergic disease ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Term infants

2

633

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.81, 1.19]

4 Asthma ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Term infants

2

673

Risk Ratio (M‐H, Fixed, 95% CI)

1.16 [0.79, 1.71]

4.2 Preterm infants

1

489

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.66, 1.34]

5 Asthma ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Term infants

1

89

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.20, 1.02]

6 Asthma ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Term infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.82, 1.53]

7 Dermatitis/eczema ‐ infant incidence Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 Term infants

6

1422

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.80, 1.07]

7.2 Preterm infants

1

484

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.71, 1.29]

8 Dermatitis/eczema ‐ childhood incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 Term infants

2

154

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.34, 1.24]

9 Dermatitis/eczema ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 Term infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.59, 1.09]

10 Allergic rhinitis ‐ infant incidence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 Term infants

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

1.20 [0.18, 8.26]

10.2 Preterm infants

1

475

Risk Ratio (M‐H, Fixed, 95% CI)

0.40 [0.18, 0.89]

11 Allergic rhinitis ‐ childhood prevalence Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 Term infants

2

635

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.83, 1.25]

12 Food allergy ‐ infant incidence Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 Term infants

2

442

Risk Ratio (M‐H, Fixed, 95% CI)

0.62 [0.38, 1.02]

12.2 Preterm infants

1

473

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.67, 2.31]

13 Food allergy ‐ childhood incidence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 Term infants

1

65

Risk Ratio (M‐H, Fixed, 95% CI)

2.27 [0.25, 20.68]

14 Food allergy ‐ childhood prevalence Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 Term infants

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.06, 1.19]
Figuras y tablas -
Comparison 6. Higher versus lower PUFA intake: subgrouped by gestational age at birth
Ir a la tabla de la revisión
Comparison 7. Higher versus lower PUFA intake: sensitivity analysis

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Asthma Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Infant incidence

1

489

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.66, 1.34]

2 Dermatitis/eczema Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Infant incidence

1

484

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.71, 1.29]

3 Allergic rhinitis Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Infant incidence

1

475

Risk Ratio (M‐H, Fixed, 95% CI)

0.40 [0.18, 0.89]

4 Food allergy Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Infant incidence

1

473

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.67, 2.31]
Figuras y tablas -
Comparison 7. Higher versus lower PUFA intake: sensitivity analysis
Ir a la tabla de la revisión